Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abeona Therapeutics (ABEO) Cost of Revenue (2020 - 2025)

Abeona Therapeutics (ABEO) has 8 years of Cost of Revenue data on record, last reported at $100000.0 in Q2 2025.

  • For Q2 2025, Cost of Revenue changed N/A year-over-year to $100000.0; the TTM value through Jun 2025 reached $1.7 million, changed N/A, while the annual FY2023 figure was $1.6 million, 256.67% up from the prior year.
  • Cost of Revenue reached $100000.0 in Q2 2025 per ABEO's latest filing, up from $30000.0 in the prior quarter.
  • Across five years, Cost of Revenue topped out at $32.9 million in Q1 2021 and bottomed at $30000.0 in Q3 2023.
  • Average Cost of Revenue over 4 years is $5.8 million, with a median of $225000.0 recorded in 2022.
  • Peak YoY movement for Cost of Revenue: changed 0.0% in 2021, then surged 350.0% in 2023.
  • A 4-year view of Cost of Revenue shows it stood at $32.9 million in 2021, then crashed by 99.7% to $100000.0 in 2022, then plummeted by 70.0% to $30000.0 in 2023, then skyrocketed by 233.33% to $100000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were $100000.0 in Q2 2025, $30000.0 in Q3 2023, and $1.6 million in Q2 2023.